Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BIO 
Bio-Rad Laboratories Inc (BIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: BIO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $315.33
1 Year Target Price $315.33
| 2 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.71% | Avg. Invested days 41 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.76B USD | Price to earnings Ratio - | 1Y Target Price 315.33 |
Price to earnings Ratio - | 1Y Target Price 315.33 | ||
Volume (30-day avg) 6 | Beta 0.94 | 52 Weeks Range 211.43 - 387.99 | Updated Date 07/16/2025 |
52 Weeks Range 211.43 - 387.99 | Updated Date 07/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -76.53 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -85.16% | Operating Margin (TTM) 9.72% |
Management Effectiveness
Return on Assets (TTM) 1.55% | Return on Equity (TTM) -27.52% |
Valuation
Trailing PE - | Forward PE 32.26 | Enterprise Value 6569480787 | Price to Sales(TTM) 2.66 |
Enterprise Value 6569480787 | Price to Sales(TTM) 2.66 | ||
Enterprise Value to Revenue 2.59 | Enterprise Value to EBITDA -13.07 | Shares Outstanding 22142400 | Shares Floating 18657507 |
Shares Outstanding 22142400 | Shares Floating 18657507 | ||
Percent Insiders 16.14 | Percent Institutions 93.04 |
Upturn AI SWOT
Bio-Rad Laboratories Inc
Company Overview
History and Background
Bio-Rad Laboratories, Inc. was founded in 1952 in Berkeley, California. Initially focused on biochemical research supplies, it expanded into clinical diagnostics and life science research products, becoming a major player in these fields.
Core Business Areas
- Life Science: Develops, manufactures, and markets a wide range of reagents, instruments, and software used in biological and medical research. This includes products for genomics, proteomics, cell biology, and bioprocessing.
- Clinical Diagnostics: Offers a comprehensive line of in vitro diagnostics products for clinical laboratories, including quality controls, instruments, and reagents for immunoassay, clinical chemistry, and molecular diagnostics.
Leadership and Structure
Norman Schwartz is the Chairman and CEO. The company operates with a functional organizational structure, encompassing various departments such as R&D, manufacturing, marketing, sales, and finance.
Top Products and Market Share
Key Offerings
- Droplet Digital PCR (ddPCR): ddPCR is a highly precise method for quantifying nucleic acids. Competitors include Thermo Fisher Scientific (QX200 ddPCR System) and QIAGEN (QIAcuity Digital PCR System). Market share of ddPCR can vary regionally but Bio-Rad is a major player. Market analysis and reports estimate Bio-Rad's ddPCR system accounts for about 30-40% market share.
- Antibodies and Reagents: Bio-Rad offers a wide range of antibodies and reagents for various research applications. Key Competitors include Thermo Fisher Scientific, Cell Signaling Technology, Abcam and Merck KGaA. These are crucial to the life science research market. Market share estimates place Bio-Rad in the top 5 antibody suppliers worldwide, estimated at 5-10%.
- Quality Controls: Bio-Rad offers quality controls for use in clinical diagnostics labs. Competitors include Roche, Abbott, and Siemens Healthineers. It is estimated that Bio-Rad accounts for 10-15% of the quality control market.
Market Dynamics
Industry Overview
The life science and clinical diagnostics industries are experiencing strong growth due to advancements in genomics, personalized medicine, and increasing demand for diagnostic testing. These industries are highly regulated and competitive.
Positioning
Bio-Rad is a well-established player in both the life science and clinical diagnostics markets. Its competitive advantages include a broad product portfolio, strong brand reputation, and global distribution network.
Total Addressable Market (TAM)
The TAM for Bio-Rad's markets (Life Science & Clinical Diagnostics) is estimated at hundreds of billions USD. Bio-Rad has a solid position and is well poised to capture TAM value.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Diverse product portfolio
- Global distribution network
- High investment in R&D
Weaknesses
- Dependence on key products
- Exposure to regulatory changes
- Slower growth in certain product segments
Opportunities
- Expanding into emerging markets
- Developing new diagnostic technologies
- Acquiring complementary businesses
- Partnering with pharmaceutical companies
Threats
- Intense competition
- Price pressures
- Technological obsolescence
- Economic downturns
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Danaher Corporation (DHR)
- Agilent Technologies (A)
- Roche Holding AG (RO.SW)
Competitive Landscape
Bio-Rad competes with larger and smaller companies in various segments. Its strengths lie in specific technologies and customer relationships, while larger competitors benefit from scale and broader product portfolios.
Major Acquisitions
S1000 touch Thermal Cycler
- Year: 2012
- Acquisition Price (USD millions):
- Strategic Rationale: Added to PCR product lines
Growth Trajectory and Initiatives
Historical Growth: Bio-Rad has experienced steady growth driven by product innovation and strategic acquisitions.
Future Projections: Analyst projections vary, but generally anticipate continued growth in line with industry trends.
Recent Initiatives: Recent initiatives include new product launches, acquisitions, and partnerships to expand market reach.
Summary
Bio-Rad is a strong player in the life science and clinical diagnostics markets, with a diverse product portfolio and global reach. Its focus on innovation and strategic acquisitions is fueling growth. Competitive pressures and economic uncertainties are factors to watch out for. Continued investments in R&D and expansion into emerging markets should help.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Financial Reports
- Industry Analysis Reports
- Company Press Releases
- Third party equity research reports
- Market data platforms
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bio-Rad Laboratories Inc
Exchange NYSE | Headquaters Hercules, CA, United States | ||
IPO Launch date 1966-01-01 | Chairman & CEO Mr. Norman D. Schwartz | ||
Sector Healthcare | Industry Medical Devices | Full time employees 7700 | Website https://www.bio-rad.com |
Full time employees 7700 | Website https://www.bio-rad.com | ||
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.